Cargando…
Modulation of the Human T Cell Response by a Novel Non-Mitogenic Anti-CD3 Antibody
The agonistic anti-human CD3ε antibody (Ab), OKT3, has been used to control acute transplant rejection. The in vivo administration of OKT3 was previously shown to induce the partial depletion of T cells and unresponsiveness (anergy) in the remaining CD4(+) T cells. However, this therapy is also asso...
Autores principales: | Shiheido, Hirokazu, Chen, Chen, Hikida, Masaki, Watanabe, Takeshi, Shimizu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978038/ https://www.ncbi.nlm.nih.gov/pubmed/24710513 http://dx.doi.org/10.1371/journal.pone.0094324 |
Ejemplares similares
-
Human T cells expressing BEND3 on their surface represent a novel subpopulation that preferentially produces IL-6 and IL-8
por: Shiheido, Hirokazu, et al.
Publicado: (2014) -
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
por: Sugita, Sunao, et al.
Publicado: (2017) -
Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus
por: Morita, Masashi, et al.
Publicado: (2022) -
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015) -
Role of anti-CD4-binding site antibodies in modulating gp120-specific CD4 T cell and antibody responses
por: Visciano, ML, et al.
Publicado: (2006)